Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study

BMC Neurology

Volumn 13, Issue , 2013, Pages

  Agashivala, Neetu ^a   Wu, Ning ^b   Abouzaid, Safiya ^a   Wu, You ^b   Kim, Edward ^a   Boulanger, Luke ^b   Brandes, David W ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b EVIDERA   (United States)

^c Sweetwater Neurology   (United States)

Author keywords

Compliance; Discontinuation; Fingolimod; Medication persistence; Multiple sclerosis; Patient adherence

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SELF ADMINISTRATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHARMACY; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROPORTIONAL HAZARDS MODELS; PROPYLENE GLYCOLS; RETROSPECTIVE STUDIES; SPHINGOSINE; TIME FACTORS;

EID: 84884955488     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-138     Document Type: Article

References (17)

1. Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care. 2013, 19:S15-20.
2. Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol. 2011, 9:409-16. 10.2174/157015911796557911, 3151595, 22379455.
3. Compston A, Coles A. Multiple sclerosis. Lancet 2002, 359:1221-1231. 10.1016/S0140-6736(02)08220-X, 11955556.
4. Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 2005, 4:CD002127.
5. Girouard N, Soucy N. Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents. Patient Prefer Adherence 2011, 5:101-108. 3063656, 21448467.
6. Portaccio E, Amato MP. Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs 2009, 23:453-462. 10.2165/00023210-200923060-00001, 19480465.
7. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 2010, 30:89-100. 10.2165/11533330-000000000-00000, 20067327.
8. Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS. Persistence and compliance of deferoxamine versus deferasirox in medicaid patients with sickle-cell disease. J Clin Pharm Ther 2012, 37:173-181. 10.1111/j.1365-2710.2011.01276.x, 21592159.
9. Halpern R, Agarwal S, Borton L, Oneacre K, Lopez-Bresnahan MV. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis. Adv Ther 2011, 28:761-775. 10.1007/s12325-011-0054-9, 21870169.
10. Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, Suchet L, Hyde R, Balla I, Frohman EM, et al. The global adherence project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011, 18:69-77. 10.1111/j.1468-1331.2010.03110.x, 20561039.
11. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005, 11:46-50. 10.1191/1352458505ms1131oa, 15732266.
12. Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J, Jeffery D, Cohen B, Mankowski K, Guarnaccia J, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009, 256:568-576. 10.1007/s00415-009-0096-y, 19444532.
13. Brod M, Rousculp M, Cameron A. Understanding compliance issues for daily self-injectable treatment in ambulatory care settings. Patient Prefer Adherence 2008, 2:129-136. 2770412, 19920953.
14. Braithwaite RS, Kozal MJ, Chang CC, Roberts MS, Fultz SL, Goetz MB, Gibert C, Rodriguez-Barradas M, Mole L, Justice AC. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS 2007, 21:1579-1589. 10.1097/QAD.0b013e3281532b31, 3460378, 17630553.
15. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004, 9(Suppl 4):28-37.
16. Sormani MP, Li DK, Bruzzi P, Stubinski B, Cornelisse P, Rocak S, De Stefano N. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology 2011, 77:1684-1690. 10.1212/WNL.0b013e31823648b9, 21975200.
17. Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011, 28:51-61. 10.1007/s12325-010-0093-7, 21153000.